Olink

Olink®
Part of Thermo Fisher Scientific

The proteogenomic landscape of the human kidney and implications for cardio-kidney-metabolic health

Nature Medicine, 2025

Hirohama D., Fadista J., Ha E., Liu H., Abedini A., Levinsohn J., Vassalotti A., Zeng L., Li C., Mohandes S., Vitale S., Shungin D., Nguyen T., Niewczas M., Olsson N., McAllister F., Karihaloo A., Susztak K.

Disease areaApplication areaSample typeProducts
Metabolic Diseases
CVD
Nephrology
Pathophysiology
Tissue Lyste
Olink Explore HT

Olink Explore HT

Abstract

Nearly one-third of the global population is affected by cardio-kidney-metabolic (CKM) diseases; however, the molecular mechanisms underlying CKM diseases are poorly understood. Here we show that tissue proteomics provide critical insights not captured by tissue gene expression or blood proteomics information by performing whole-genome and RNA sequencing and proteomics analysis of human kidney samples (n = 337), and we generated a publicly available database. Via Bayesian co-localization and Mendelian randomization analyses of kidney protein quantitative trait loci and 36 CKM genome-wide association studies, we prioritized 89 proteins for CKM traits. We prioritized relationships that could underlie the interconnectedness of CKM traits and discovered multiple and targetable mechanisms for CKM diseases, including the potential role of kidney angiopoietin-like protein 3 (ANGPTL3) in serum lipid levels and kidney function as well as the role of charged multivesicular body protein 1A in kidney function and hypertension. Notably, we identify pathways with confluence of evidence from genetic loci, tissue gene expression and protein levels for CKM traits. In summary, our large-scale kidney proteomics study uncovers proteins and targetable mechanisms prioritized for CKM diseases.

Read publication ↗